S&P 500   4,066.83 (+1.47%)
DOW   32,523.09 (+0.93%)
QQQ   303.11 (+1.56%)
AAPL   148.14 (+1.79%)
MSFT   263.78 (+0.87%)
FB   199.71 (-0.16%)
GOOGL   2,308.04 (+0.84%)
AMZN   2,254.20 (+1.71%)
TSLA   751.34 (+3.72%)
NVDA   178.11 (+3.17%)
BABA   90.42 (+4.56%)
NIO   16.51 (+13.47%)
AMD   100.80 (+6.96%)
CGC   5.87 (+2.44%)
MU   73.68 (+4.56%)
T   20.46 (+0.89%)
GE   76.27 (+2.20%)
F   13.41 (+2.76%)
DIS   107.57 (+2.27%)
AMC   12.43 (+6.15%)
PFE   51.01 (+0.67%)
PYPL   78.27 (+0.80%)
NFLX   188.18 (+0.90%)
S&P 500   4,066.83 (+1.47%)
DOW   32,523.09 (+0.93%)
QQQ   303.11 (+1.56%)
AAPL   148.14 (+1.79%)
MSFT   263.78 (+0.87%)
FB   199.71 (-0.16%)
GOOGL   2,308.04 (+0.84%)
AMZN   2,254.20 (+1.71%)
TSLA   751.34 (+3.72%)
NVDA   178.11 (+3.17%)
BABA   90.42 (+4.56%)
NIO   16.51 (+13.47%)
AMD   100.80 (+6.96%)
CGC   5.87 (+2.44%)
MU   73.68 (+4.56%)
T   20.46 (+0.89%)
GE   76.27 (+2.20%)
F   13.41 (+2.76%)
DIS   107.57 (+2.27%)
AMC   12.43 (+6.15%)
PFE   51.01 (+0.67%)
PYPL   78.27 (+0.80%)
NFLX   188.18 (+0.90%)
S&P 500   4,066.83 (+1.47%)
DOW   32,523.09 (+0.93%)
QQQ   303.11 (+1.56%)
AAPL   148.14 (+1.79%)
MSFT   263.78 (+0.87%)
FB   199.71 (-0.16%)
GOOGL   2,308.04 (+0.84%)
AMZN   2,254.20 (+1.71%)
TSLA   751.34 (+3.72%)
NVDA   178.11 (+3.17%)
BABA   90.42 (+4.56%)
NIO   16.51 (+13.47%)
AMD   100.80 (+6.96%)
CGC   5.87 (+2.44%)
MU   73.68 (+4.56%)
T   20.46 (+0.89%)
GE   76.27 (+2.20%)
F   13.41 (+2.76%)
DIS   107.57 (+2.27%)
AMC   12.43 (+6.15%)
PFE   51.01 (+0.67%)
PYPL   78.27 (+0.80%)
NFLX   188.18 (+0.90%)
S&P 500   4,066.83 (+1.47%)
DOW   32,523.09 (+0.93%)
QQQ   303.11 (+1.56%)
AAPL   148.14 (+1.79%)
MSFT   263.78 (+0.87%)
FB   199.71 (-0.16%)
GOOGL   2,308.04 (+0.84%)
AMZN   2,254.20 (+1.71%)
TSLA   751.34 (+3.72%)
NVDA   178.11 (+3.17%)
BABA   90.42 (+4.56%)
NIO   16.51 (+13.47%)
AMD   100.80 (+6.96%)
CGC   5.87 (+2.44%)
MU   73.68 (+4.56%)
T   20.46 (+0.89%)
GE   76.27 (+2.20%)
F   13.41 (+2.76%)
DIS   107.57 (+2.27%)
AMC   12.43 (+6.15%)
PFE   51.01 (+0.67%)
PYPL   78.27 (+0.80%)
NFLX   188.18 (+0.90%)
NYSE:PKI

PerkinElmer (PKI) Stock Forecast, Price & News

$147.60
+0.81 (+0.55%)
(As of 05/17/2022 02:27 PM ET)
Add
Compare
Today's Range
$145.86
$149.84
50-Day Range
$142.05
$184.54
52-Week Range
$137.37
$203.16
Volume
9,739 shs
Average Volume
949,651 shs
Market Capitalization
$18.62 billion
P/E Ratio
24.16
Dividend Yield
0.19%
Beta
1.16
30 days | 90 days | 365 days | Advanced Chart
Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PerkinElmer logo

About PerkinElmer

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Headlines

Diagnosing PerkinElmer - Seeking Alpha
See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
CUSIP
71404610
Employees
16,700
Year Founded
1937

Sales & Book Value

Annual Sales
$5.07 billion
Cash Flow
$13.58 per share
Book Value
$56.59 per share

Profitability

Net Income
$943.16 million
Pretax Margin
20.26%

Debt

Price-To-Earnings

Miscellaneous

Free Float
125,492,000
Market Cap
$18.62 billion
Optionable
Optionable

Company Calendar

Ex-Dividend for 5/13 Dividend
4/21/2022
Last Earnings
5/03/2022
Dividend Payable
5/13/2022
Today
5/17/2022
Next Earnings (Estimated)
7/25/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.45 out of 5 stars

Computer And Technology Sector

232nd out of 930 stocks

Analytical Instruments Industry

5th out of 32 stocks

Analyst Opinion: 2.4Community Rank: 4.4Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













PerkinElmer (NYSE:PKI) Frequently Asked Questions

Is PerkinElmer a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PerkinElmer stock.
View analyst ratings for PerkinElmer
or view top-rated stocks.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Monday, July 25th 2022.
View our earnings forecast for PerkinElmer
.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) posted its quarterly earnings data on Tuesday, May, 3rd. The medical research company reported $2.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.08 by $0.33. The medical research company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.19 billion. PerkinElmer had a net margin of 14.54% and a trailing twelve-month return on equity of 18.98%. The firm's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the business posted $3.72 EPS.
View PerkinElmer's earnings history
.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, April 28th. Investors of record on Friday, July 22nd will be given a dividend of $0.07 per share on Friday, August 12th. This represents a $0.28 dividend on an annualized basis and a yield of 0.19%. The ex-dividend date of this dividend is Thursday, July 21st.
View PerkinElmer's dividend history
.

Is PerkinElmer a good dividend stock?

PerkinElmer pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.19%. The dividend payout ratio of PerkinElmer is 4.58%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PerkinElmer will have a dividend payout ratio of 4.01% next year. This indicates that PerkinElmer will be able to sustain or increase its dividend.
View PerkinElmer's dividend history.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $2.00-$2.05 for the period, compared to the consensus earnings per share estimate of $1.69. The company issued revenue guidance of $1.20 billion-$1.22 billion, compared to the consensus revenue estimate of $1.10 billion.

What price target have analysts set for PKI?

6 brokerages have issued 1 year price objectives for PerkinElmer's stock. Their forecasts range from $50.00 to $205.00. On average, they expect PerkinElmer's share price to reach $165.64 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price.
View analysts' price targets for PerkinElmer
or view top-rated stocks among Wall Street analysts.

Who are PerkinElmer's key executives?
PerkinElmer's management team includes the following people:
  • Dr. Prahlad R. Singh Ph.D., CEO, Pres & Director (Age 57, Pay $4.15M)
  • Mr. James M. Mock, Sr. VP & CFO (Age 45, Pay $1.6M) (LinkedIn Profile)
  • Mr. Tajinder Vohra, Sr. VP of Global Operations (Age 56, Pay $1.06M)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 53, Pay $1.53M)
  • Mr. Daniel R. Tereau, Sr. VP of Strategy & Bus. Devel. (Age 54, Pay $1.18M) (LinkedIn Profile)
  • Mr. Andrew Okun, VP, Chief Accounting Officer & Treasurer (Age 52) (LinkedIn Profile)
  • Mr. Stephen Barr Willoughby, VP of Investor Relations
  • Mr. Robert Francis Friel, Advisor (Age 66)
  • Ms. Miriame Victor, Sr. VP & Chief Commercial Officer (Age 41)
  • Dr. Masoud Toloue Ph.D., Sr. VP of Diagnostics (Age 41)
What is Prahlad Singh's approval rating as PerkinElmer's CEO?

27 employees have rated PerkinElmer CEO Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among PerkinElmer's employees.

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.87%), BlackRock Inc. (6.69%), Select Equity Group L.P. (4.54%), State Street Corp (4.09%), Massachusetts Financial Services Co. MA (3.31%) and Primecap Management Co. CA (1.10%). Company insiders that own PerkinElmer stock include Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Peter Barrett, Prahlad R Singh and Sylvie Gregoire.
View institutional ownership trends for PerkinElmer
.

Which major investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., JPMorgan Chase & Co., Select Equity Group L.P., Echo Street Capital Management LLC, APG Asset Management N.V., Hsbc Holdings PLC, Panagora Asset Management Inc., and King Luther Capital Management Corp. Company insiders that have sold PerkinElmer company stock in the last year include Andrew Okun, Daniel R Tereau, James M Mock, and Sylvie Gregoire.
View insider buying and selling activity for PerkinElmer
or view top insider-selling stocks.

Which major investors are buying PerkinElmer stock?

PKI stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Swiss National Bank, Massachusetts Financial Services Co. MA, Tobam, BlackRock Inc., Boston Trust Walden Corp, Achmea Investment Management B.V., and Aaron Wealth Advisors LLC.
View insider buying and selling activity for PerkinElmer
or or view top insider-buying stocks.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $147.60.

How much money does PerkinElmer make?

PerkinElmer has a market capitalization of $18.62 billion and generates $5.07 billion in revenue each year. The medical research company earns $943.16 million in net income (profit) each year or $6.11 on an earnings per share basis.

How many employees does PerkinElmer have?

PerkinElmer employs 16,700 workers across the globe.

Does PerkinElmer have any subsidiaries?

The following companies are subsidiares of PerkinElmer: 2Cure LLC, Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, BioLegend, BioLegend CNS Inc., BioLegend China Beijing Ltd., BioLegend Europe B.V., BioLegend France SAS, BioLegend GmbH, BioLegend Inc., BioLegend Japan KK, BioLegend Shenzhen Ltd., BioLegend Taiwan Ltd., BioLegend UK Ltd., BioLegend Ventures LLC, Bioo Scientific Corporation, Biosense Technologies Pvt Ltd., Boulder Diagnostics Europe GmbH, Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio.com, DIA.Metra S.R.L., DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, Dharmacon Inc., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnostica Ltda., EUROIMMUN Diagnostics España S.L., EUROIMMUN France SAS, EUROIMMUN Hangzhou Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Diagnostics China Co. Ltd., EUROIMMUN Medical Laboratory Diagnostics South Africa Pty Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Sp. z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN South East Asia Pte Ltd., EUROIMMUN Tianjin Medical Diagnostic Technology Co. Ltd., EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.Ş., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Diagnostics Limited, Horizon Discovery, Horizon Discovery Biosciences Limited, Horizon Discovery Group Ltd., Horizon Discovery Inc., Horizon Discovery KK, Horizon Discovery Limited, Horizon Genomics GmbH, IDS Brasil Diagnósticos Ltda., Immunetics Inc., Immunodiagnostic Systems, Immunodiagnostic Systems Deutschland GmbH, Immunodiagnostic Systems France SAS, Immunodiagnostic Systems Holdings Limited, Immunodiagnostic Systems Inc., Immunodiagnostic Systems Limited, Immunodiagnostic Systems SA, Inochem S.A. de C. V., Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, Nexcelom Bioscience, Nexcelom Bioscience Holdings LLC, Nexcelom Bioscience Instruments Shanghai Co. Ltd., Nexcelom Bioscience LLC, Nexcelom Bioscience Ltd., NovaScreen Biosciences Corporation, OZ Systems International SARL, OZ Systems USA LLC, Omni International Inc., Optimization Zorn Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Diagnostic Laboratories UK Limited, Oxford Immunotec, Oxford Immunotec Asia Ltd, Oxford Immunotec Global Limited, Oxford Immunotec Ireland Limited, Oxford Immunotec KK, Oxford Immunotec Limited, Oxford Immunotec Shanghai Medical Device Co. Ltd., Oxford Immunotec USA Inc., Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Instruments Philippines Corporation, Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin-Elmer Argentina S.R.L., Perkin-Elmer de Mexico S.A., PerkinElmer Argentina Holdings LLC, PerkinElmer Automotive Research Inc., PerkinElmer BV, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Genomics Sweden AB, PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.C.A., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Puerto Rico LLC, PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics Shanghai Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Singapore Pte Ltd., PerkinElmer Hong Kong Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer India Pvt Ltd., PerkinElmer Informatics Inc., PerkinElmer Instruments Suzhou Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Ireland Ltd., PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS Germany GmbH, PerkinElmer LAS UK Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Life Sciences Singapore Pte. Ltd., PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management Chengdu Co. Ltd., PerkinElmer Management Shanghai Co. Ltd., PerkinElmer Nederland B.V. , PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp. z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Schweiz AG, PerkinElmer Shanghai Equity Investment Fund L.P., PerkinElmer Shanghai Equity Investment Fund Management Co. Ltd., PerkinElmer Shared Services Sp. z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa Pty Ltd., PerkinElmer Sverige AB, PerkinElmer Taiwan Corporation, PerkinElmer UK Holdings Ltd., PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments AB, Perten Instruments GmbH, Perten Instruments of Australia Pty Ltd., Qognit Inc., RHS Ltd, RayAl Ltd., SIRION Biotech, SIRION Biotech GmbH, SIRION Biotech International Inc., Sage Labs LLC, Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Singapore Biosciences Pte Ltd., Solus Scientific Solutions Ltd., SonoVol Inc., Suomen Bioanalytiikka Oy, Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Synthetx Limited, Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.

When was PerkinElmer founded?

PerkinElmer was founded in 1937.

What is PerkinElmer's official website?

The official website for PerkinElmer is www.perkinelmer.com.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at (781) 663-6900, via email at [email protected], or via fax at 781-663-5985.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.